Product Title: Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys, 2nd Edition (Original PDF from Publisher)
Format:
Publisher PDF, File Size = 5.40 MB
Overview (Details, Topics and Speakers):
By Larry K. Golightly, Isaac Teitelbaum, Bonita A. Simendinger, Tyree H. Kiser, Gerard R. Barber, Nancy M. Stolpman
To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications.
This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types.
Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.
Product Details
- Publisher : Springer; 2nd ed. 2021 edition (September 25, 2021)
- Language : English
- Paperback : 853 pages
- ISBN-10 : 3030586499
- ISBN-13 : 978-3030586492
- ISBN-13 : 9783030586492
- eText ISBN: 9783030586508
Delivery Method
the Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys, 2nd Edition (Original PDF from Publisher) course/book will be provided for customer as download link. download link has NO Expiry and can be used anytime.
Contact Us
contact us to our email at support@med-cme.com or fill in the form below:
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.